?? Thrilled to share that yesterday Calder’s CEO, Christopher Marshall, Ph.D., joined Dr. Jonathan Zenilman—renowned Professor of Medicine at Johns Hopkins, former Chief of Infectious Diseases, and a pivotal leader in vaccine safety—for an engaging fireside chat at the Hopkins Healthcare Business Conference. Dr. Zenilman’s expertise is nothing short of extraordinary: ?? Former Chair of the Vaccine Safety Committee for Comirnaty (the COVID-19 vaccine) ?? Current member of the Data Monitoring Committee for a leading RSV vaccine ?? Decades of leadership in infectious disease research and public health Their discussion delved into the promise and challenges of vaccine development. Huge thanks to Johns Hopkins for hosting this thought-provoking event, and to Dr. Zenilman for sharing his invaluable perspective. At Calder, we’re honored to contribute to these conversations and push the boundaries in healthcare innovation. #HealthcareLeadership #VaccineDevelopment #InfectiousDisease #InnovationInHealthcare #PublicHealth
Calder Biosciences Inc.
生物技术研究
Brooklyn，NY 547 位关注者
Improving & Saving Lives with the second generation of subunit vaccines to protect against life-threatening diseases.
关于我们
Calder Biosciences, Inc. is a nano-scale molecular engineering company that is applying its platform technology to develop novel respiratory syncytial virus (RSV) and universal Influenza vaccines that both represent multi-billion dollar market opportunities with mitigated clinical risk.
- 网站
-
https://www.calderbiosciences.com
Calder Biosciences Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 2-10 人
- 总部
- Brooklyn，NY
- 类型
- 私人持股
- 创立
- 2018
- 领域
- RSV Vaccine、Universal Influenza、BioPharma、Vaccine、Biotechnology、DS-Cav1、Vaccines for Old Adults、Protein Science、Pre-Clinical、Clinical、Subunit Protein、immunogens、Antigens、Pathogens、Respiratory Diseases、SARS-CoV2、EBV、HIV、Virus和Maternal Vaccines
地点
-
主要
获取路线
140 58th Street
Building A, Unit 8J
US，NY，Brooklyn，11220
Calder Biosciences Inc.员工
-
Christopher P. Marshall, Ph.D.
Chief Executive Officer at Calder Biosciences Inc.
-
John Shiver, Ph.D.
Head of R&D, Vibrant Biomedicines; Special Advisor, F Prime Capital;| Vaccines & Biologics | Global R&D Leader | P&L | Board Director | Pharma |…
-
Dirk Pleimes
CEO / CMO Pentixapharm AG Serial Founder & Biotechnology entrepreneur
-
Mark Yondola
Co-founder and Chief Scientific Officer at Calder Biosciences
动态
-
?? Thrilled to share that yesterday Calder’s CEO, Christopher Marshall, Ph.D., joined Dr. Jonathan Zenilman—renowned Professor of Medicine at Johns Hopkins, former Chief of Infectious Diseases, and a pivotal leader in vaccine safety—for an engaging fireside chat at the Hopkins Healthcare Business Conference. Dr. Zenilman’s expertise is nothing short of extraordinary: ?? Former Chair of the Vaccine Safety Committee for Comirnaty (the COVID-19 vaccine) ?? Current member of the Data Monitoring Committee for a leading RSV vaccine ?? Decades of leadership in infectious disease research and public health Their discussion delved into the promise and challenges of vaccine development. Huge thanks to Johns Hopkins for hosting this thought-provoking event, and to Dr. Zenilman for sharing his invaluable perspective. At Calder, we’re honored to contribute to these conversations and push the boundaries in healthcare innovation. #HealthcareLeadership #VaccineDevelopment #InfectiousDisease #InnovationInHealthcare #PublicHealth
-
-
Jeremy’s comments are a “must read”for those concerned about the risks to our healthcare system and, much more specifically, our health as a species.
Today, we face an extraordinary threat to public health: Aaron Siri, a lawyer closely aligned with Robert F. Kennedy Jr., who is nominated to head HHS has petitioned the FDA to revoke approval of the polio vaccine. This move was incredibly ill-advised and if acted on poses a direct risk to the health and safety of Americans. If it moves forward under a new administration it will undermine decades of medical progress and endangers countless lives by opening the door to the resurgence of a disease that once devastated this nation. Polio is a devastating, highly contagious disease that can paralyze and kill. For decades, vaccines have shielded Americans from this crippling scourge. Yet now, astonishingly, some seek to unravel this lifesaving legacy by challenging vaccine approvals—an act of profound recklessness that endangers every citizen. Polio doesn’t negotiate. It disables. It kills. It robs people of breath and mobility. It leaves lifelong scars through paralysis and post-polio syndrome, even decades after recovery. This isn’t theory; it’s fact. The tools to prevent this horror exist: vaccines. They have virtually eliminated polio from the U.S. and curbed countless other deadly diseases. The benefits are undeniable. The science is irrefutable. The cost of complacency? Catastrophic. To allow preventable diseases like polio to resurge in the U.S. is sheer insanity. It’s a betrayal of our nation’s health and of decades of medical progress. We must reject efforts to remove vaccines from the armamentarium of modern medicine. Vaccines aren’t just a defense against disease—they’re a testament to human ingenuity. The tireless work of scientists, as highlighted in groundbreaking research, continues to expand our capacity to protect lives. Public health requires robust vaccination campaigns, industry support, and collective trust. As we look to the future lets unite against the forces of misinformation and anti-science. Lets stand for health, progress, and the lives vaccines save. Reject the erosion of public health. Vaccinate. Advocate. Protect our children and the nation. #VaccinesWork #PublicHealth #PolioPrevention #ScienceSavesLives
-
-
We are excited to announce that Calder Biosciences has graduated from the Endless Frontier Labs 2023-2024 cohort! It has been an incredible journey working alongside EFL mentors, NYU Stern MBA students, and the other great companies selected for the Life Sciences track. Endless Frontier Labs is a New York-based mentorship program supporting promising startups across the globe by helping to scale their business, grow their teams, and advance human welfare through science and technology-based entrepreneurship. If you are a startup company in the tech or life sciences space, apply to the 2024-2025 EFL cohort here at https://lnkd.in/dRQmqyy The program is completely free for participating startups.
-
Calder is excited to share that our recent Nature Communications article, "Engineered dityrosine-bonding of the RSV prefusion F protein imparts stability and potency advantages", is featured on the Editors' Highlights page as one of the 50 best published papers in our area: https://lnkd.in/e4ED8Qag